Review Opinion on Expected Routine Related Transactions for 2026
Everbright Securities Co., Ltd. (hereinafter referred to as "Everbright Securities" or "the Sponsor") is the sponsor for the initial public offering of Nantong Taihe Chemical Co., Ltd. (hereinafter referred to as "Taihe" or "the Company"). In accordance with the "Regulations on the Management of Securities Issuance and Listing Sponsorship," the "Shenzhen Stock Exchange GEM Listing Rules" (hereinafter referred to as "the GEM Listing Rules"), and the "Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operations of GEM Listed Companies" (hereinafter referred to as "Self-Regulatory Guidelines No. 2"), Everbright Securities has conducted a prudent review of the expected routine related transactions for 2026. The review opinions are as follows:
1. Basic Information on Routine Related Transactions
(1) Overview of Routine Related Transactions
For the needs of daily operations, the Company has made reasonable estimates of the routine related transactions for 2026 in accordance with the "Company Law of the People's Republic of China," the "Shenzhen Stock Exchange GEM Listing Rules," the "Self-Regulatory Guidelines No. 2," and the "Management Measures for Related Transactions of Nantong Taihe Chemical Co., Ltd." (hereinafter referred to as "the Articles of Association"). The Company held the seventh meeting of the fourth board of directors on April 23, 2026, and approved the proposal on the expected routine related transactions for 2026. This proposal was reviewed by the independent directors, who expressed their agreement, and the sponsor issued a review opinion. Mr. Tian Xiaohong, the related director, abstained from voting on this proposal. This related transaction does not constitute a major asset reorganization as defined by the "Measures for the Administration of Major Asset Restructuring of Listed Companies." The proposal still needs to be submitted to the Company's annual general meeting of shareholders in 2025 for deliberation.